0000950170-24-106152.txt : 20240912 0000950170-24-106152.hdr.sgml : 20240912 20240912210953 ACCESSION NUMBER: 0000950170-24-106152 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20240912 FILED AS OF DATE: 20240912 DATE AS OF CHANGE: 20240912 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Mazumdar Claire CENTRAL INDEX KEY: 0002034671 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-42271 FILM NUMBER: 241296271 MAIL ADDRESS: STREET 1: BICARA THERAPEUTICS INC. STREET 2: 116 HUNTINGTON AVENUE, SUITE 703 CITY: BOSTON STATE: MA ZIP: 02116 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Bicara Therapeutics Inc. CENTRAL INDEX KEY: 0002023658 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 245 MAIN STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-785-8308 MAIL ADDRESS: STREET 1: 245 MAIN STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 3 1 ownership.xml 3 X0206 3 2024-09-12 0 0002023658 Bicara Therapeutics Inc. BCAX 0002034671 Mazumdar Claire BICARA THERAPEUTICS INC. 116 HUNTINGTON AVENUE, SUITE 703 BOSTON MA 02116 true true false false Chief Executive Officer Common Stock 309892 D Stock Option (Right to Buy) 4.10 2031-11-19 Common Stock 99315 D Stock Option (Right to Buy) 4.44 2032-10-04 Common Stock 48682 D Stock Option (Right to Buy) 4.44 2032-10-04 Common Stock 16227 D Stock Option (Right to Buy) 3.79 2033-04-05 Common Stock 138000 D Stock Option (Right to Buy) 3.79 2033-08-08 Common Stock 326107 D Stock Option (Right to Buy) 5.45 2033-12-14 Common Stock 595012 D Stock Option (Right to Buy) 9.24 2034-08-06 Common Stock 1141342 D The shares underlying this option vest in sixteen equal quarterly installments following November 8, 2021, subject to the Reporting Person's continued service on each such vesting date. The shares underlying this option vest in twelve equal quarterly installments following October 4, 2022, subject to the Reporting Person's continued service on each such vesting date. The shares underlying this option vest in four equal quarterly installments following October 4, 2025, subject to the Reporting Person's continued service on each such vesting date. The shares underlying this option vest in sixteen equal quarterly installments following April 5, 2023, subject to the Reporting Person's continued service on each such vesting date. The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date. The shares underlying this option vest in sixteen equal quarterly installments following December 14, 2023, subject to the Reporting Person's continued service on each such vesting date. The shares underlying this option vest in sixteen equal quarterly installments following August 6, 2024, subject to the Reporting Person's continued service on each such vesting date. Exhibit 24 - Power of Attorney /s/ Lara Meisner, Attorney-in-Fact 2024-09-12 EX-24 2 ck0002023658-ex24.htm EX-24 EX-24

 

LIMITED POWER OF ATTORNEY

 

The undersigned hereby constitutes and appoints each of Ryan Cohlhepp and Lara Meisner of Bicara Therapeutics Inc. (the “Company”) and Gabriela Morales-Rivera of Goodwin Procter LLP, signing singly, and with full power of substitution, the undersigned’s true and lawful attorney-in-fact to:

(1) execute for and on behalf of the undersigned, in the undersigned’s capacity as an officer, director, and/or securityholder of the Company, from time to time the following U.S. Securities and Exchange Commission (“SEC”) forms: (i) Form ID, including any attached documents (such as Update Passphrase Authentication), to effect the assignment of codes to the undersigned to be used in the transmission of information to the SEC using the EDGAR System; (ii) Form 3, Initial Statement of Beneficial Ownership of Securities, including any attached documents; (iii) Form 4, Statement of Changes in Beneficial Ownership of Securities, including any attached documents; (iv) Form 5, Annual Statement of Beneficial Ownership of Securities in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended, and the rules thereunder, including any attached documents; (v) Schedules 13D and 13G; and (vi) amendments of each thereof, in accordance with the Securities Exchange Act of 1934, as amended, and the rules thereunder, including any attached documents;

 

(2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4 or 5, Schedule 13D or 13G, or any amendment(s) thereto and timely file such form(s) with the SEC and any securities exchange, national association or similar authority; and

 

(3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

 

The undersigned hereby grants to each such attorney-in-fact, acting singly, full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned’s responsibilities to comply with Section 16 or Regulation 13D-G of the Securities Exchange Act of 1934, as amended. The undersigned hereby agrees to indemnify the attorneys-in-fact and the Company from and against any demand, damage, loss, cost or expense arising from any false or misleading information provided by the undersigned to the attorneys-in-fact.

 

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file such forms with respect to the undersigned’s holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact. This Power of Attorney supersedes any prior power of attorney in connection with the undersigned’s capacity as an officer and/or director of the Company. This Power of Attorney shall expire as to any individual attorney-in-fact if such attorney-in-fact ceases to be an employee of the Company or Goodwin Procter LLP, as the case may be.

 

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of September 12, 2024.

 

 

/s/ Claire Mazumdar

 

 

Signature

 

 

 

 

 

Claire Mazumdar

 

 

Print Name